基于免疫检查点抑制剂的联合治疗策略研究进展

Advances in immune checkpoint inhibitors combined with other treatments

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)疗法是目前最受关注的肿瘤免疫疗法之一,已被批准为多种肿瘤治疗的一线用药。然而,单一的ICIs疗法具有疗效有限、易耐药等缺陷。因此,开发联合治疗策略以提高ICIs疗效,成为抗肿瘤领域的研究热点。文章首先介绍了ICIs的新型作用靶点,并结合ICIs产生治疗抵抗的机制,系统介绍了现有疗法(如化疗、放疗、热治疗、抗血管生成治疗、肿瘤疫苗、细胞因子治疗、过继细胞疗法等)与ICIs的联合治疗策略,并深入探讨了其增强肿瘤杀伤作用的机制,为临床针对患者病理特征进行个性化联合治疗提供参考。

As one of the most attention-attracting immunotherapy,immune checkpoint inhibitors(ICIs)have been approved as the first-line drugs for the therapy of various types of cancers.Nevertheless,the single application of ICIs exhibited limited efficacy,and it is easy to develop drug resistance.Therefore,the development of combination therapies become a hot topic in this field to improve the efficacy of ICIs therapy.This article describes some new ICIs targets,reveals the mechanisms of resistance,and introduces the current status of combination other therapies with ICIs therapy systematically including chemotherapy,radiotherapy,hyperthermia,antiangiogenic therapy,tumor vaccines,cytokine therapy and adoptive cellular therapy.Furthermore,the synergistic mechanism of combination therapy to enhance antitumor effect.Thus,this article provides solid references for personalized combination therapy according to the pathological characteristics of patients.